Study Compares Nanodropper Adaptor Versus Conventional Eye Drops for Glaucoma

Nanodropper announced the publication of a company-sponsored study, "An Evaluation of the Efficacy and Safety of Timolol Maleate 0.5% Microdrops Administered with the Nanodropper," in the journal Ophthalmology.

The prospective, multicenter, randomized, parallel-group, single-masked, active-controlled, non-inferiority trial enrolled glaucoma patients and demonstrated there was no clinically significant difference in the IOP-lowering effects of microdrops administered with the Nanodropper Adaptor compared to conventional eyedrops of timolol. This was observed at all time points throughout the 8-hour study. Subjects in the microdrops arm also experienced a significantly smaller decrease in heart rate compared to those that received conventional drops, demonstrating there could be an enhanced safety profile of using a microdrop of timolol compared to a conventionally-sized eye drop, according to Nanodropper.

The Nanodropper Adaptor is the first and only sterile adaptor for eye drop bottles that reduces eye drop volume to just what the eye can absorb, reducing medication waste and financial barriers for patients and clinics. 

The full study in Ophthalmology can be found here.